OrsoBio: bringing obesity mechanisms to bear

With $97 million in funding to date, OrsoBio is sufficiently capitalized to reach key clinical milestones for each of three programs with novel mechanisms in the metabolic arena, all of which the start-up has in-licensed from other biopharmas.

Incubated by Samsara BioCapital and led by former Gilead Sciences Inc. (NASDAQ:GILD) liver disease head Mani Subramanian, OrsoBio Inc. has collected a handful of products from biopharmas that have increasingly favored oncology or other disease areas, freeing up metabolic programs now housed under a single roof...